Effect of food on the absorption of frusemide and bumetanide in man
1. The influence of food on the absorption of frusemide and bumetanide was compared in two separate randomized crossover studies. 2. On three separate occasions frusemide 40 mg was administered to eight healthy male volunteers intravenously, orally in the fasting state and orally after a standard br...
Gespeichert in:
| Veröffentlicht in: | British journal of clinical pharmacology Jg. 42; H. 6; S. 743 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
England
01.12.1996
|
| Schlagworte: | |
| ISSN: | 0306-5251 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | 1. The influence of food on the absorption of frusemide and bumetanide was compared in two separate randomized crossover studies. 2. On three separate occasions frusemide 40 mg was administered to eight healthy male volunteers intravenously, orally in the fasting state and orally after a standard breakfast. Blood and urine were collected at intervals over 8 h and urine alone for a further 16 h. The study was then repeated in nine healthy volunteers using intravenous and oral bumetanide 2 mg. 3. Breakfast significantly reduced the peak plasma concentration of frusemide from 2.35 +/- 0.49 to 0.51 +/- 0.19 mg l-1 (95% confidence intervals (95% CI) = 1.39 to 2.28 mg l-1) and delayed the time to peak concentration from 0.69 +/- 0.21 to 1.91 +/- 0.93 h (95% CI = 0.41 to 2.03 h). The oral bioavailability of frusemide was significantly reduced by approximately 30% (75.6 +/- 10.6 to 43.2 +/- 16.8%; 95% CI = 13.5 to 51.4%). 4. With bumetanide, the meal also significantly reduced the peak concentration from 0.097 +/- 0.015 to 0.036 +/- 0.012 mg l-1 (95% CI = 0.048 to 0.073 mg l-1) and delayed the time to peak from 0.53 +/- 0.08 to 1.36 +/- 0.72 h (95% CI = 0.23 to 1.44 h). However, food had no statistically significant effect on the bioavailability and urinary recovery of bumetanide. 5. In this study, the absorption of bumetanide was affected less than frusemide by food. |
|---|---|
| AbstractList | 1. The influence of food on the absorption of frusemide and bumetanide was compared in two separate randomized crossover studies. 2. On three separate occasions frusemide 40 mg was administered to eight healthy male volunteers intravenously, orally in the fasting state and orally after a standard breakfast. Blood and urine were collected at intervals over 8 h and urine alone for a further 16 h. The study was then repeated in nine healthy volunteers using intravenous and oral bumetanide 2 mg. 3. Breakfast significantly reduced the peak plasma concentration of frusemide from 2.35 +/- 0.49 to 0.51 +/- 0.19 mg l-1 (95% confidence intervals (95% CI) = 1.39 to 2.28 mg l-1) and delayed the time to peak concentration from 0.69 +/- 0.21 to 1.91 +/- 0.93 h (95% CI = 0.41 to 2.03 h). The oral bioavailability of frusemide was significantly reduced by approximately 30% (75.6 +/- 10.6 to 43.2 +/- 16.8%; 95% CI = 13.5 to 51.4%). 4. With bumetanide, the meal also significantly reduced the peak concentration from 0.097 +/- 0.015 to 0.036 +/- 0.012 mg l-1 (95% CI = 0.048 to 0.073 mg l-1) and delayed the time to peak from 0.53 +/- 0.08 to 1.36 +/- 0.72 h (95% CI = 0.23 to 1.44 h). However, food had no statistically significant effect on the bioavailability and urinary recovery of bumetanide. 5. In this study, the absorption of bumetanide was affected less than frusemide by food. 1. The influence of food on the absorption of frusemide and bumetanide was compared in two separate randomized crossover studies. 2. On three separate occasions frusemide 40 mg was administered to eight healthy male volunteers intravenously, orally in the fasting state and orally after a standard breakfast. Blood and urine were collected at intervals over 8 h and urine alone for a further 16 h. The study was then repeated in nine healthy volunteers using intravenous and oral bumetanide 2 mg. 3. Breakfast significantly reduced the peak plasma concentration of frusemide from 2.35 +/- 0.49 to 0.51 +/- 0.19 mg l-1 (95% confidence intervals (95% CI) = 1.39 to 2.28 mg l-1) and delayed the time to peak concentration from 0.69 +/- 0.21 to 1.91 +/- 0.93 h (95% CI = 0.41 to 2.03 h). The oral bioavailability of frusemide was significantly reduced by approximately 30% (75.6 +/- 10.6 to 43.2 +/- 16.8%; 95% CI = 13.5 to 51.4%). 4. With bumetanide, the meal also significantly reduced the peak concentration from 0.097 +/- 0.015 to 0.036 +/- 0.012 mg l-1 (95% CI = 0.048 to 0.073 mg l-1) and delayed the time to peak from 0.53 +/- 0.08 to 1.36 +/- 0.72 h (95% CI = 0.23 to 1.44 h). However, food had no statistically significant effect on the bioavailability and urinary recovery of bumetanide. 5. In this study, the absorption of bumetanide was affected less than frusemide by food.1. The influence of food on the absorption of frusemide and bumetanide was compared in two separate randomized crossover studies. 2. On three separate occasions frusemide 40 mg was administered to eight healthy male volunteers intravenously, orally in the fasting state and orally after a standard breakfast. Blood and urine were collected at intervals over 8 h and urine alone for a further 16 h. The study was then repeated in nine healthy volunteers using intravenous and oral bumetanide 2 mg. 3. Breakfast significantly reduced the peak plasma concentration of frusemide from 2.35 +/- 0.49 to 0.51 +/- 0.19 mg l-1 (95% confidence intervals (95% CI) = 1.39 to 2.28 mg l-1) and delayed the time to peak concentration from 0.69 +/- 0.21 to 1.91 +/- 0.93 h (95% CI = 0.41 to 2.03 h). The oral bioavailability of frusemide was significantly reduced by approximately 30% (75.6 +/- 10.6 to 43.2 +/- 16.8%; 95% CI = 13.5 to 51.4%). 4. With bumetanide, the meal also significantly reduced the peak concentration from 0.097 +/- 0.015 to 0.036 +/- 0.012 mg l-1 (95% CI = 0.048 to 0.073 mg l-1) and delayed the time to peak from 0.53 +/- 0.08 to 1.36 +/- 0.72 h (95% CI = 0.23 to 1.44 h). However, food had no statistically significant effect on the bioavailability and urinary recovery of bumetanide. 5. In this study, the absorption of bumetanide was affected less than frusemide by food. |
| Author | Barron, W Prescott, L F Li Kam Wa, T C McCrindle, J L |
| Author_xml | – sequence: 1 givenname: J L surname: McCrindle fullname: McCrindle, J L organization: Clinical Pharmacology Unit, Royal Infirmary, Edinburgh, UK – sequence: 2 givenname: T C surname: Li Kam Wa fullname: Li Kam Wa, T C – sequence: 3 givenname: W surname: Barron fullname: Barron, W – sequence: 4 givenname: L F surname: Prescott fullname: Prescott, L F |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/8971430$$D View this record in MEDLINE/PubMed |
| BookMark | eNotj7FOwzAQhj0UlbbwCEie2BLOdnyORxQVilSJBebIjh2RqrFLnEjw9qQi0-m7_7uT_i1ZhRg8IZRBzqDAp1POBMqMMy5zpjXmAIUu8p8V2YAAzCSX7JZsUzoBMMFQrsm61IoVAjak2retb0YaW9rG6GgMdPzy1NgUh8vYzXhNhin5vnPzPjhqp96PJlyxC7Q34Y7ctOac_P0yd-TzZf9RHbLj--tb9XzMGomiyFhhSjRNq4VW1nKDRkApsFEoHXLlVaMNM56BK4UpYTasddrNN8xxkJLvyOP_38sQvyefxrrvUuPPZxN8nFKtSuSoFZ_Fh0WcbO9dfRm63gy_9dKa_wGwFVoV |
| CitedBy_id | crossref_primary_10_1002_bdd_1874 crossref_primary_10_1016_j_ccl_2020_01_004 crossref_primary_10_1016_j_dmpk_2023_100518 crossref_primary_10_1159_000509741 crossref_primary_10_1111_jfbc_13317 crossref_primary_10_1592_phco_24_6_630_34736 crossref_primary_10_1007_s10741_019_09851_9 crossref_primary_10_1016_j_ejpb_2013_09_002 crossref_primary_10_1016_S1036_7314_03_80016_4 crossref_primary_10_1016_j_cardfail_2014_05_007 crossref_primary_10_1007_s00228_024_03723_4 crossref_primary_10_1007_s11095_006_9127_x crossref_primary_10_1007_s13318_012_0097_6 crossref_primary_10_1016_j_jpba_2012_03_018 crossref_primary_10_1177_2048872618768488 crossref_primary_10_1002_bdd_1818 crossref_primary_10_2215_CJN_09630818 crossref_primary_10_3390_pharmaceutics15020542 crossref_primary_10_3390_pharmaceutics13071035 crossref_primary_10_1517_14740330903499240 crossref_primary_10_1124_dmd_110_037457 crossref_primary_10_1542_neo_6_8_e392 crossref_primary_10_1007_s40265_021_01666_z crossref_primary_10_1007_s40262_025_01524_1 crossref_primary_10_1023_B_PHAM_0000022410_89709_c3 crossref_primary_10_1097_00000441_200001000_00004 crossref_primary_10_1517_14740338_2_6_549 crossref_primary_10_1046_j_1523_1755_2003_00124_x crossref_primary_10_1016_j_ahj_2014_12_009 crossref_primary_10_1016_j_ijpharm_2003_08_007 crossref_primary_10_1111_j_1365_2125_2007_03035_x crossref_primary_10_1111_j_1527_5299_2003_02399_x crossref_primary_10_7759_cureus_21369 crossref_primary_10_1016_j_ejpb_2004_03_001 crossref_primary_10_1208_s12248_020_00509_1 crossref_primary_10_1016_S0002_9629_15_40678_0 crossref_primary_10_1111_j_1365_2125_2007_03016_x crossref_primary_10_1177_0091270004269557 crossref_primary_10_34067_KID_0006372021 crossref_primary_10_1002_bmc_5825 crossref_primary_10_1542_neo_13_7_e410 crossref_primary_10_2165_00003495_200262100_00005 crossref_primary_10_2174_1574885514666190126141424 crossref_primary_10_1097_CRD_0000000000000763 crossref_primary_10_1007_s11936_015_0436_4 crossref_primary_10_3390_jcm13010012 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1046/j.1365-2125.1996.00494.x |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| ExternalDocumentID | 8971430 |
| Genre | Clinical Trial Randomized Controlled Trial Journal Article |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OC 23N 24P 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB AOIJS ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG CGR COF CS3 CUY CVF D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS ECM EIF EJD EMOBN ESX EX3 F00 F01 F04 F5P FIJ FUBAC G-S G.N GODZA GX1 H.X HF~ HGLYW HYE HZI HZ~ IHE IPNFZ IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LSO LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NPM O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K ROL RPM RX1 SUPJJ TEORI TR2 UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WVDHM WXI WXSBR X7M XG1 YFH YOC YUY ZGI ZXP ZZTAW ~IA ~WT 7X8 AAMMB AEFGJ AEYWJ AGXDD AIDQK AIDYY |
| ID | FETCH-LOGICAL-c5634-14a86acf9397bb2a6a30836c765d627e7c9a1ae10d83a80b2abbd9d86a1d20552 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 51 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=10.1046/j.1365-2125.1996.00494.x&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0306-5251 |
| IngestDate | Sun Nov 09 11:38:40 EST 2025 Wed Feb 19 02:35:57 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5634-14a86acf9397bb2a6a30836c765d627e7c9a1ae10d83a80b2abbd9d86a1d20552 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1365-2125.1996.00494.x |
| PMID | 8971430 |
| PQID | 78626972 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_78626972 pubmed_primary_8971430 |
| PublicationCentury | 1900 |
| PublicationDate | December 1996 |
| PublicationDateYYYYMMDD | 1996-12-01 |
| PublicationDate_xml | – month: 12 year: 1996 text: December 1996 |
| PublicationDecade | 1990 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | British journal of clinical pharmacology |
| PublicationTitleAlternate | Br J Clin Pharmacol |
| PublicationYear | 1996 |
| SSID | ssj0013165 |
| Score | 1.6976182 |
| Snippet | 1. The influence of food on the absorption of frusemide and bumetanide was compared in two separate randomized crossover studies. 2. On three separate... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 743 |
| SubjectTerms | Adult Area Under Curve Biological Availability Bumetanide - pharmacokinetics Chromatography, High Pressure Liquid Cross-Over Studies Diuretics - pharmacokinetics Food-Drug Interactions Furosemide - pharmacokinetics Humans Intestinal Absorption Male |
| Title | Effect of food on the absorption of frusemide and bumetanide in man |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/8971430 https://www.proquest.com/docview/78626972 |
| Volume | 42 |
| WOSCitedRecordID | wos10.1046/j.1365-2125.1996.00494.x&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07a8MwEBZp06FL36XpU0PJFFHLli0LCqWEhi4NHlLIFvQyZIidxk0h_74n2SZdSocuBj9kxHE6fbrHdwjdO69SZGJKLGWGMKYVUQBMSJTrQEaaOg4U32yCj8fpdCqyDnpsa2FcWmVrE72hNqV2PvIH7qC34OHT8oO4nlEutto00NhB3QiAjFuWfPojhkB9I0kHiuG4FdMmj6eJafrsLtjdXbmei0cwwTz90S8w0283o8P_TfQIHTQwEz_XenGMOrY4Qf2s5qneDPBkW3ZVDXAfZ1sG680pGtacxrjMcV6WBpcFBpyIparKlTcx_s1qXdnF3MDzwmAFNg5wprudF3ghizP0PnqZDF9J022B6DiJGKFMponUuQCEolQoExk55mrNk9gkIbdcC0mlpYFJI5kG8IVSRhgYQ00YxHF4jnaLsrAXCMNvQhnCQSi0jEkwEdQ697MSuSd44z1014puBtrsQhSysOW6mrXC66HzWvqzZU26MUuF69QeXP459Art-8xqn3Jyjbo5LGN7g_b01-e8Wt16HYHrOHv7BiKzw8s |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+food+on+the+absorption+of+frusemide+and+bumetanide+in+man&rft.jtitle=British+journal+of+clinical+pharmacology&rft.au=McCrindle%2C+J+L&rft.au=Li+Kam+Wa%2C+T+C&rft.au=Barron%2C+W&rft.au=Prescott%2C+L+F&rft.date=1996-12-01&rft.issn=0306-5251&rft.volume=42&rft.issue=6&rft.spage=743&rft_id=info:doi/10.1046%2Fj.1365-2125.1996.00494.x&rft_id=info%3Apmid%2F8971430&rft_id=info%3Apmid%2F8971430&rft.externalDocID=8971430 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0306-5251&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0306-5251&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0306-5251&client=summon |